Latest news with #lawsuit
Daily Mail
3 hours ago
- Daily Mail
The cruel act that left happy-go-lucky student at $40,000-a-year private school isolated, suffering PTSD and working at a supermarket
A former student is suing his prestigious Melbourne grammar school after he began suffering from a post-traumatic stress disorder after a violent incident on campus. The young man - who has asked to remain anonymous - alleged a fellow student at Caulfield Grammar School poured hot liquid over his head and face in late 2019. 'At 15 years old, I was just settling into a new school with high hopes and big dreams,'the now-20-year-old said in a statement shared with Daily Mail Australia. 'What happened to me wasn't an accident; it wasn't a misunderstanding. It was an act of cruelty, and I was the target. 'The physical pain was horrible, but the emotional damage has stayed with me far longer.' In a writ filed with Victoria's County Court on June 17, the former student listed injuries including post-traumatic stress disorder, scarring, and pain and shock. He said he incurred hospital and medical expenses, as well as claiming a loss of earnings and loss of earning capacity. 'As a result of his injury, the Plaintiff repeated Year 10 and did a non-scored VCE in 2020. Presently, (he) is working in a supermarket,' the writ said. 'I haven't been the same. My mum said I used to be happy-go-lucky, always smiling, always social,' he said. 'Now I rarely go out with friends, and I often feel isolated. I don't trust easily, not after what happened. That one moment changed the trajectory of my life.' He described how, to most people, he looks 'fine' but added: 'When I'm out in the sun, the affected skin reacts, and I also suffer from severe PTSD'. The writ describes at least 15 alleged failings by Caulfield Grammar which the young man's solicitor Aristea Nikolakakis, from Shine Lawyers, has outlined. 'We allege the school was warned about this student's propensity for violence and yet did nothing to protect our client,' she said in a statement. 'We allege our client had been physically threatened by this student in the past and yet nothing was done to keep him safe.' She alleged the school breached its duty of care to the young man by not taking action over the threat and that it had 'ample warning' that he was 'in danger'. 'This wasn't an isolated issue,' Ms Nikolakakis said. 'This was an ongoing situation the school was aware of between the other student and my client, and the school failed to protect my client by intervening when they should have.' The young man said the management of the alleged incident on the school's Wheelers Hill campus is 'what made it worse' and claimed teachers assumed he was at fault because he was new. 'They believed the other student, someone who had been there longer. The school did me a disservice, not only by failing to hold the student accountable in a meaningful way, but also by failing to support me during... and after the incident,' he said. He also said Caulfield Grammar never called an ambulance and that his 18-year-old brother had to take him to the hospital. 'I had strong ambitions, especially in soccer,' he said, adding that a change of rules then stumped his hopes of earning the role of captain. 'That leadership role, that recognition of my hard work, was taken away, just like everything else that year. 'I still wonder what life might have looked like if that incident had never happened.' Daily Mail Australia has contacted Caulfield Grammar for comment.
Yahoo
4 hours ago
- Business
- Yahoo
SINOVAC Board of Directors Prevails Against Advantech/Prime's Lawsuit in Hong Kong
Hong Kong Court denies Advantech/Prime's petition for Interim Relief Clears another legal hurdle for distribution of the US$55.00 per common share special cash dividend declared by the current SINOVAC Board to be paid on or about July 7, 2025 BEIJING, June 27, 2025--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has prevailed against the latest lawsuit filed by Advantech/Prime Success ("Advantech/Prime") in Hong Kong. This result follows Advantech/Prime's recently failed petition in New York last week, which was a repeated attempt by the purported PIPE Investors to block or delay a hearing for interim relief sought by the Company et al at the Antiguan High Court and to interfere with the payment of the US$55.00 per common share special cash dividend to valid shareholders of the Company as declared by the current SINOVAC Board. On June 24, Advantech/Prime delivered via email an ex parte Summons to SINOVAC, 1Globe Capital LLC ("1Globe") and OrbiMed Partners Master Fund Limited ("OrbiMed") for an "interim-interim" injunction application (the "Application"). Vivo Capital also sought to join the Application on June 26. After the emergent hearing at the High Court of Hong Kong on June 27, the court refused to grant any of the relief sought in the Summons. Among other things, the judge also criticized Advantech/Prime for: Failing to comply with the duty of full and frank disclosure in the Application; and The alleged urgency of the Application being self-induced by Advantech/Prime. The court also ordered that legal costs incurred in the Application by SINOVAC, 1Globe and OrbiMed be compensated by Advantech/Prime, with quantum to be assessed. Advantech/Prime's continued multi-jurisdictional lawfare is intended to interfere with rightful dividend payments to SINOVAC's valid shareholders and distract from its long history of self-serving schemes. These schemes include: Privatization attempt at a below-market price in 2016; Invalid PIPE transaction at a below-market price in 2018, which materially diluted SINOVAC shareholders and was made at a time when the Company did not need the capital; US$7.5 million debt investment into Sinovac Life Sciences Co., Ltd. ("SLS"), a wholly owned subsidiary of SINOVAC, in exchange for a 7.5% equity interest in SLS in 2020, at a time when the Company did not need the capital and which has resulted in over US$500 million of distributions made to Advantech/Prime to date while common shareholders have received nothing; and Baseless and wasteful legal action in 2025 to interfere with the dividend payment unless Advantech/Prime is able to double dip on dividends already received from SLS. The current SINOVAC Board remains committed to its mission of restoring fairness, delivering value, and protecting the rights of all valid shareholders. Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card "AGAINST" Proposal 1 to remove the current Board and "AGAINST" Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S. and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ("SEC") and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. View source version on Contacts Investor and Media Contact FGS GlobalSinovac@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
5 hours ago
- CBS News
Jim Harbaugh added to lawsuit against ex-Michigan assistant coach Matt Weiss
Former University of Michigan coach Jim Harbaugh was added Friday to a lawsuit against U of M and former assistant football coach Matt Weiss, who is accused of hacking into the computer accounts of college athletes across the U.S. to look for intimate photos. Attorneys claim Harbaugh, who is now head coach of the Los Angeles Chargers, and others knew that Weiss was seen viewing private information on a computer in December 2022 but still allowed him to continue working as co-offensive coordinator in a national playoff game roughly a week later. Michigan athletic director Warde Manuel and other officials were also added to the lawsuit in federal court in Detroit. "The university's delay in taking meaningful protective action until after a high-stakes game sends a clear message: Student welfare was secondary," said Parker Stinar, who is the lead lawyer in a class-action lawsuit arising from a criminal investigation of Weiss. Messages seeking comment from Manuel and Harbaugh were not immediately returned Friday. In addition to Weiss, another lawsuit named the university's Board of Regents and the software company, Keffer Keffer Development Services, which worked with U of M. Separately, Weiss has been charged with identity theft and unauthorized computer access from 2015 to 2023. The indictment says he got access to the social media, email and cloud storage accounts of more than 2,000 college athletes, as well as more than 1,300 students or alumni from schools across the U.S., to find private images, primarily of women. He has pleaded not guilty. "Had Harbaugh implemented basic oversight of his staff, plaintiffs and the class would have been protected against predators such as Weiss," the updated lawsuit states. "Instead, Weiss was a highly compensated asset that was promoted by and within the football program, from which position he was able to, and did, target female student athletes." The lawsuit says a staff member saw Weiss viewing private information at Schembechler Hall, headquarters for the football team, around Dec. 21, 2022, and reported it before Michigan played Texas Christian University in a playoff game days later on Dec. 31. Weiss was fired a few weeks later in January 2023 during an investigation of his computer use. Earlier this year, after charges were filed, Harbaugh told reporters that he didn't know anything about Weiss' troubles until after the playoff game. He said the allegations were "shocking." Weiss worked for Harbaugh's brother, John, on the coaching staff of the NFL's Baltimore Ravens before joining the Michigan team in 2021. The lawsuit says Weiss's university computer had encryption software that had to be disabled by an external vendor as part of the investigation. Authorities disclosed in April that thousands of intimate photos and videos were found on his electronic devices and cloud storage accounts. Note: The video above previously aired on April 14, 2025.
The Independent
6 hours ago
- Politics
- The Independent
New Hampshire lawsuit seeks to stop politicization of youth center abuse victims' fund
Lawyers representing hundreds of men and woman who claim they were abused at New Hampshire's youth detention center filed a class action lawsuit Friday seeking to prevent the independent administrator of the state's settlement fund for victims from being replaced with a political appointee. Lawmakers created the settlement fund in 2022, pitching it as a 'victim-centered' and 'trauma-informed' alternative to litigation that would be run by a neutral administrator appointed by the state Supreme Court. But the Republican-led Legislature changed that process through last-minute additions to the state budget approved Thursday and signed into law by Gov. Kelly Ayotte on Friday. Under the new provisions taking effect July 1, the governor will have the authority to hire and fire the fund's administrator, and the attorney general — also a political appointee — would have veto power over settlement awards. In affidavits filed with their complaint, the lead plaintiffs said the change amounts to a bait and switch that reignited the skepticism they initially felt about the settlement process but tried to put aside. 'I never would have shared the full story of what happened to me if I did not think I would be heard by someone impartial,' said a woman identified only as Jane Doe, who said she ran away from home to escape sexual abuse only to be further abused in state custody. 'I feel incredibly betrayed by the state's actions, but this is just the latest in a long list of betrayals by the state, so maybe I should not be surprised,' she said. 'This also makes me wonder whether the state will next betray the promise of confidentiality, because it seems like their word does not mean anything to them.' Another plaintiff, Andrew Foley, described being diagnosed with PTSD, not from his time as a combat soldier in Iraq but from the physical and sexual abuse he suffered as a child. 'As I understand it, the State will now decide for itself how much my claim is worth. That is the opposite of a fair process,' his affidavit said. 'As I always believed, the state cannot be trusted.' Neither Ayotte nor Attorney General John Formella responded to requests for comment Friday. More than 1,300 people have sued since 2020 alleging that they were physically or sexually abused in state custody as children, most of them at the Sununu Youth Services Center in Manchester. Only one case has gone to trial, resulting in a $38 million verdict, though the state is trying to slash it to $475,000. Two other cases have been settled for $10 million and $4.5 million. The state also has brought criminal charges against former workers, with two convictions and two mistrials so far. Many of the alleged victims put their lawsuits on hold and applied to the settlement fund, which caps payouts at $2.5 million. As of March 31, 296 cases had been settled, with an average award of $543,000, according to the most recently available statistics. The lawsuit filed Friday seeks a temporary restraining order to prevent the governor from firing the current administrator, former state Supreme Court Chief Justice John Broderick.
Associated Press
6 hours ago
- Business
- Associated Press
SINOVAC Board of Directors Prevails Against Advantech/Prime's Lawsuit in Hong Kong
BEIJING--(BUSINESS WIRE)--Jun 27, 2025-- The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced it has prevailed against the latest lawsuit filed by Advantech/Prime Success ('Advantech/Prime') in Hong Kong. This result follows Advantech/Prime's recently failed petition in New York last week, which was a repeated attempt by the purported PIPE Investors to block or delay a hearing for interim relief sought by the Company et al at the Antiguan High Court and to interfere with the payment of the US$55.00 per common share special cash dividend to valid shareholders of the Company as declared by the current SINOVAC Board. On June 24, Advantech/Prime delivered via email an ex parte Summons to SINOVAC, 1Globe Capital LLC ('1Globe') and OrbiMed Partners Master Fund Limited ('OrbiMed') for an 'interim-interim' injunction application (the 'Application'). Vivo Capital also sought to join the Application on June 26. After the emergent hearing at the High Court of Hong Kong on June 27, the court refused to grant any of the relief sought in the Summons. Among other things, the judge also criticized Advantech/Prime for: The court also ordered that legal costs incurred in the Application by SINOVAC, 1Globe and OrbiMed be compensated by Advantech/Prime, with quantum to be assessed. Advantech/Prime's continued multi-jurisdictional lawfare is intended to interfere with rightful dividend payments to SINOVAC's valid shareholders and distract from its long history of self-serving schemes. These schemes include: The current SINOVAC Board remains committed to its mission of restoring fairness, delivering value, and protecting the rights of all valid shareholders. Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card ' AGAINST ' Proposal 1 to remove the current Board and ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S. and (646) 543-1968 outside the U.S. or via email at [email protected]. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under 'Category 1 Preventative Biological Products' and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at [email protected]. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. View source version on CONTACT: Investor and Media Contact FGS Global [email protected] KEYWORD: ASIA PACIFIC HONG KONG INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: The Board of Directors of Sinovac Biotech Ltd. Copyright Business Wire 2025. PUB: 06/27/2025 07:12 PM/DISC: 06/27/2025 07:12 PM
